1. Home
  2. SSTK vs GYRE Comparison

SSTK vs GYRE Comparison

Compare SSTK & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Shutterstock Inc.

SSTK

Shutterstock Inc.

HOLD

Current Price

$19.32

Market Cap

675.2M

Sector

Technology

ML Signal

HOLD

Logo Gyre Therapeutics Inc.

GYRE

Gyre Therapeutics Inc.

HOLD

Current Price

$7.60

Market Cap

755.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SSTK
GYRE
Founded
2003
2002
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
675.2M
755.7M
IPO Year
2012
N/A

Fundamental Metrics

Financial Performance
Metric
SSTK
GYRE
Price
$19.32
$7.60
Analyst Decision
Buy
Strong Buy
Analyst Count
2
2
Target Price
$25.00
$17.00
AVG Volume (30 Days)
218.9K
63.5K
Earning Date
11-05-2025
11-07-2025
Dividend Yield
7.03%
N/A
EPS Growth
66.87
N/A
EPS
1.69
0.04
Revenue
$1,020,010,000.00
$107,265,000.00
Revenue This Year
$11.41
$11.59
Revenue Next Year
N/A
$26.31
P/E Ratio
$11.14
$196.47
Revenue Growth
13.06
2.13
52 Week Low
$14.35
$6.11
52 Week High
$38.80
$14.42

Technical Indicators

Market Signals
Indicator
SSTK
GYRE
Relative Strength Index (RSI) 42.94 45.47
Support Level $18.56 $7.36
Resistance Level $19.58 $8.50
Average True Range (ATR) 0.77 0.34
MACD 0.04 -0.03
Stochastic Oscillator 35.91 19.65

Price Performance

Historical Comparison
SSTK
GYRE

About SSTK Shutterstock Inc.

Shutterstock Inc is a U.S.-based company that is engaged in the provision of digital content. The content segment, whose offerings include licenses for Images, Footage, Music, 3 Dimensional, and Generative AI content. Data, Distribution, and Service offerings address customer demand for products and services that are beyond its Content licenses. The company generates the majority of its revenue from Content offerings. Geographically the company generates the majority of its revenue from the Domestic market, but also has its presence in Europe and Rest of the Countries.

About GYRE Gyre Therapeutics Inc.

Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.

Share on Social Networks: